6ce117eb6a591f79dbfc296489c44579081b719594acfb41d6e105073b666ebc

Diagnostic test revenue (USD, thousands)

Other revenue (USD, thousands)

Total revenue (USD, thousands)

Cost of services (USD, thousands)

Gross profit (USD, thousands)

Research and development (USD, thousands)

Selling and marketing (USD, thousands)

General and administrative (USD, thousands)

Impairment loss (USD, thousands)

Other operating expenses, net (USD, thousands)

Loss from operations (USD, thousands)

Change in fair value of warrants (USD, thousands)

Change in fair value of warrants and contingent liabilities (USD, thousands)

Change in fair value of warrants and earn-out contingent liabilities (USD, thousands)

Interest expense, net (USD, thousands)

Interest (expense) income, net (USD, thousands)

Other income, net (USD, thousands)

Other (expense) income, net (USD, thousands)

Other expense, net (USD, thousands)

Total non-operating expenses, net (USD, thousands)

Total non-operating (expense) income, net (USD, thousands)

Total non-operating income, net (USD, thousands)

Loss before income taxes (USD, thousands)

Income tax (expense) benefit (USD, thousands)

Income tax benefit (USD, thousands)

Net loss (USD, thousands)

Other comprehensive income (loss), net of tax (USD, thousands)

Other comprehensive income, net of tax (USD, thousands)

Other comprehensive loss, net of tax (USD, thousands)

Comprehensive loss (USD, thousands)

Weighted average shares outstanding of Class A common stock (shares)

Basic and diluted loss per share, Class A common stock (USD, per share)

Basic and diluted net loss per share, Class A common stock (USD, per share)

46c548d4d2fb435b075bd75f3b8880a75f4c7ecfaba898e54a7dd46057149be5

Cash and cash equivalents (USD, thousands)

Marketable securities (USD, thousands)

Accounts receivable (USD, thousands)

Due from related parties (USD, thousands)

Inventory, net (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Operating lease right-of-use assets (USD, thousands)

Property and equipment, net (USD, thousands)

Intangible assets, net (USD, thousands)

Other assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable and accrued expenses (USD, thousands)

Due to related parties (USD, thousands)

Short-term lease liabilities (USD, thousands)

Other current liabilities (USD, thousands)

Total current liabilities (USD, thousands)

Long-term debt, net of current portion (USD, thousands)

Long-term lease liabilities (USD, thousands)

Other liabilities (USD, thousands)

Deferred taxes (USD, thousands)

Total liabilities (USD, thousands)

Class A common stock, $ 0.0001 par value (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated deficit (USD, thousands)

Accumulated other comprehensive income (USD, thousands)

Total stockholders’ equity (USD, thousands)

Total liabilities and stockholders’ equity (USD, thousands)

6afe64f1e91c8e6922664278b5fb55b77a64c1b038eb38f6d7bf78bb641629dc

GeneDx

- Patients with third-party insurance

- Institutional customers

- Self-pay patients

Legacy Sema4

Other Revenue

Total Revenue

663711879f426efa9560d5d3a661bb67ad0a9747f89e894bc5b6de306c094aaa

Number of exome and genome tests (tests)

Percentage of total test results that are exome and genome (percent)

166505cfb1f5c0c1f50e32fcc15af7618b9c4e3b29ab21267ba70c97e486a265

GeneDx Holdings Corp (WGS)

Financials